



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

Dear registered shareholder(s),

2 April 2026

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, CStone Pharmaceuticals (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any documents issued or to be issued by the Company, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.cstonepharma.com/ and the HKExnews website at www.hkexnews.hk/ in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of all future Corporate Communications, the Company recommends you provide your email address by scanning the QR code printed on the reply form enclosed. Alternatively, you may sign and return the reply form to the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, People’s Republic of China. If you do not complete and return the reply form by 24 April 2026, you will be deemed to have consented to receive the Company’s Corporate Communications on the Company’s or HKExnews website. In the circumstances, the Company will make all future Corporate Communications available on the Company’s or the HKExnews website and you can read all future Corporate Communications via the Website Version, and all future Actionable Corporate Communications in printed form will be sent to you by post at the address provided by you (if so provided) or your address as it appears in the Company’s register of members.

It is the responsibility of a registered shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications^(Note) to the email address provided by a registered shareholder without receiving any “non-delivery message”.

As Actionable Corporate Communications^(Note) are important Corporate Communications that seek your instructions on how to exercise your rights or make an election as a shareholder of the Company, it is of paramount importance to ensure that the email address to be provided by you is valid and functional at all times; otherwise you may not be able to receive the Actionable Corporate Communications^(Note) on time or at all so as to exercise your rights or make an election as a shareholder of the Company promptly within the timeframe required under the Actionable Corporate Communications^(Note). If the Company has attempted to send the Actionable Corporate Communications^(Note) in electronic form to the email address provided by you above and subsequently received a non-delivery message, the Company will re-send the relevant Actionable Corporate Communications^(Note) in printed form (accompanied with a request for your functional email address to facilitate electronic dissemination of Actionable Corporate Communications^(Note) in future) to the address provided by you (if so provided) or your address as shown in the Company’s register of members.

If you wish to receive the Corporate Communications in printed form, please complete the reply form electronically at <https://forms.office.com/r/UCFgE1uzuE> or complete and return the Reply Form to the Company.

Should you have any queries relating to this letter, please contact the Company via e-mail at ir@cstonepharma.com.

Yours faithfully,
By order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

REPLY FORM 回條

To: CStone Pharmaceuticals (the "Company")
22/F, New Bund Times Square, No. 399 West Haiyang Road,
Pudong New District, Shanghai, People's Republic of China

致： 基石藥業（「本公司」）
中華人民共和國上海市浦東新區
海陽西路 399 號前灘時代廣場 22 樓

(Please **choose ONLY ONE** of the options below)

(請從以下選項中只選擇其中一項)

Options 1/選項 1:

Provide complete the reply form by scanning the QR code

透過掃描二維碼填妥回覆表格

Returning this Reply Form is **NOT required** if Option 1 is chosen.

如選擇了選項 1，無須交回本回條。

QR Code

二維碼



Options 2/選項 2:

Please provide the name of securities holder(s) and mark "✓" in the below box

請提供證券持有人姓名並在以下方格內劃上「✓」號

(Please **choose ONLY ONE** of the options below)

(請從以下選項中只選擇其中一項)

Name of Securities holder(s) 證券持有人姓名: _____

I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications^(Note 3) of the Company via electronic dissemination

本人/吾等現以書面提供本人/吾等的電子郵件地址，以確保收到以下本公司通過電子方式發佈的可供採取行動的未來公司通訊^(附註3)

Email address 電郵地址: _____

I/we hereby request for receipt of Corporate Communications* in printed form and noted that this instruction is valid only for one year starting from the receipt date of instruction. ^(Note 5)

本人/吾等現要求收取公司通訊^{*}印刷版，並已知悉本指示由收取指示日期起計一年內有效。^(附註5)

Name of contact person 聯絡人姓名: _____

Address 地址: _____

Signature(s): ^(Note 1)

簽名: ^(附註 1)

Contact number:

聯絡電話號碼: _____

Date:

日期: _____

Notes 附註:

1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.

請清楚填妥。閣下之所有資料，如屬聯名股東，則本回條須由所有聯名股東聯合簽署，方為有效。

2. Any Reply Form with no signature or otherwise incorrectly completed will be void.

任何回條若未有簽署或在其他方面填寫不正確，則本回條將會作廢。

3. If the Company does not receive a functional email address in your reply, you will be unable to receive notifications regarding the publication of Corporate Communications*. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

如本公司沒有收到閣下的有效電子郵件地址，閣下將無法收到有關發佈公司通訊^{*}的通知。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。

4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

如閣下通過二維碼、電郵、回條及/或其他方式提供多於一個的電子郵件地址，只有閣下最後提供的電子郵件地址將會被用於登記。

5. If you mark "✓" in the box, no email address will be registered and only Corporate Communications* in printed form will be received.

如閣下在方格內劃上「✓」號，將不會有電子郵件地址被登記，只有公司通訊^{*}的印刷版會被收取。

6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

為免存疑，在本回條上的任何額外指示，本公司將不予處理。

* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form.

除非另有註明，公司通訊乃指本公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT

收集個人資料聲明

(i) "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").

本聲明中所指的「個人資料」與香港法例第 486 章《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。

(ii) Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

閣下於本回條所提供的個人資料將用於(包括但不限於)有關本公司以電子方式發布公司通訊及就閣下持有的公司證券有關的其他事宜上與閣下聯絡。閣下是自願向本公司提供個人資料。若閣下未能提供足夠資料，本公司可能無法處理閣下在本回條上所延的指示及/或要求。

(iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, share registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.

本公司可就任何所說明的用途或在法例規定的情況下，將閣下的個人資料披露或轉移給本公司的附屬公司、股份過戶處、及/或其他公司或團體，並將在適當期間保留該等個人資料作核實及紀錄用途。

(iv) You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the privacy officer of the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, People's Republic of China or by email at ir@estonepharma.com. 閣下有權根據《私隱條例》的條文查閱及/或修改閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至本公司(地址為中華人民共和國上海市浦東新區海陽西路 399 號前灘時代廣場 22 樓)向隱私主任提出，或發送電郵至 ir@estonepharma.com。

Mailing Label 郵寄標籤

CStone Pharmaceuticals
基石藥業
22/F, New Bund Times Square, No. 399 West Haiyang Road
Pudong New District, Shanghai, People's Republic of China
中華人民共和國上海市浦東新區
海陽西路 399 號前灘時代廣場 22 樓

Please cut the mailing label and stick it on an envelope to return this form to us.

當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。